# AusperBio

> AusperBio is a clinical-stage biopharmaceutical company operating in the United States and China that develops antisense oligonucleotide (ASO) therapies aimed at a functional cure for chronic hepatitis B. Built on its proprietary Med-Oligo ASO platform and targeted delivery technology, its lead candidate AHB-137 is an unconjugated ASO advancing into Phase III trials in China, with early data showing a 30% functional cure rate in a subset of patients. Founded in 2019 and headquartered in San Mateo, California, the company has raised over $200 million to date.

- **Founded:** 2019
- **Headquarters:** San Mateo, California, United States
- **Founders:** Guofeng Cheng (Co-Founder & CEO), Chris Yang (Co-Founder & Chief Scientific Officer)
- **Team size:** ~9 employees (per available data)
- **Products:** AHB-137, Med-Oligo ASO Platform
- **Notable:** AHB-137 monotherapy achieved a 30% functional cure rate at Week 72 in HBe-negative patients with baseline HBsAg 100-1,000 IU/mL on stable nucleos(t)ide analogue therapy, Received China CDE clearance to advance AHB-137 into a Phase III clinical trial for chronic hepatitis B, Presented interim Phase IIb AHB-137 data in a late-breaking abstract at EASL Congress 2025

## Products & services

- **AHB-137** — Lead candidate: a novel unconjugated, dual-mechanism antisense oligonucleotide designed to achieve a functional cure for chronic hepatitis B. Completed a global Phase I trial, advanced through Phase II studies, and received China CDE clearance to enter Phase III.
- **Med-Oligo ASO Platform** — Proprietary antisense oligonucleotide platform combining novel ASO design insights with targeted delivery technology, intended to enhance efficacy and expand ASO therapeutics across viral infections, metabolic conditions, genetic disorders, and immune diseases.

## Achievements

- AHB-137 monotherapy achieved a 30% functional cure rate at Week 72 in HBe-negative patients with baseline HBsAg 100-1,000 IU/mL on stable nucleos(t)ide analogue therapy
- Received China CDE clearance to advance AHB-137 into a Phase III clinical trial for chronic hepatitis B
- Presented interim Phase IIb AHB-137 data in a late-breaking abstract at EASL Congress 2025
- Raised more than $200 million cumulatively, including three financings within roughly a year
- Built a proprietary Med-Oligo ASO platform with targeted delivery technology

## Latest updates

- **2025-09** — Raised $63 million in Series B2 financing co-led by Qiming Venture Partners to accelerate AHB-137 pivotal development and expand global Phase II studies.
- **2025-07** — Received China CDE clearance to advance AHB-137 into a Phase III clinical trial for chronic hepatitis B.
- **2025-05** — Raised $50 million in a Series B+ round to advance its functional-cure program.
- **2025** — Reported AHB-137 monotherapy achieving a 30% functional cure rate at Week 72 in a defined HBe-negative patient subset.
- **2024-12** — Secured $73 million in Series B financing to advance a functional cure for chronic hepatitis B.

## Links

- Website: https://ausperbio.com
- LinkedIn: http://www.linkedin.com/company/ausperbio

---

Profile page: https://yespress.io/ausperbio
Published by YesPress — https://yespress.io
Last updated: 2026-07-13